Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Neuroendocrine Tumors
Management of Advanced Neuroendocrine Tumors
There are now multiple approved treatments and several promising trials with different agents, including some directed therapies, for patients with NETs. The sequencing of these treatments is controversial and will become more complicated as further drugs are approved. Clinicians need to stay current on the knowledge of benefits and risks, including the potential for lifetime radiation toxicity, of the multiple acceptable treatment strategies and apply high-level clinical evidence and expert advice to individualize the treatment and maximize outcomes.
This program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Identify key patient and clinical factors that influence choice for patients with various presentations of advanced neuroendocrine tumors (NETs).
- Select optimal treatment selection for patients with carcinoid syndrome.
- Describe clinical trials investigating new systemic therapies for advanced NETs.
Jonathan R. Stosberg, MD
Moffitt Cancer Center
Ghassan El-Haddad, MD
Moffitt Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses no relevant financial relationships:
Ghassan El-Haddad, MD
The faculty listed below discloses the following relevant financial relationships:
Jonathan R. Strosberg, MD
Ipsen: Product/Speakers Bureau
Lexicon Pharmaceuticals, Inc.: Product/Speakers Bureau
Novartis Pharmaceuticals Corporation: Consulting Fee
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Weinstein (Sinclair); Kathy Ann Smith, CHCP
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Deborah Freedman-Cass, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.81 contact hour.
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-19-112-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until 12/16/2020. PAs should only claim credit commensurate with the extent of their participation.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 0.75 CE contact hour. Activity Code: I00039983; Approval #: 190004509
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.81 ANCC contact hours
- 0.75 CCM clock hours
- 0.75 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing